PFIZER INC
About PFIZER INC
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $62.6B
- Net income
- $7.8B
- Total assets
- $208.2B
- Market cap
- $148.4B
- Gross margin
- 74.3%
- Operating margin
- 12.0%
- Net margin
- 12.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $62.6B
- Cost of revenue
- $16.1B
- Gross profit
- $46.5B
- Operating expenses
- $39.0B
- Operating income
- $7.5B
- Income tax
- -$266.0M
- Net income
- $7.8B
- EPS (basic)
- $1.37
- EPS (diluted)
- $1.36
Balance sheet
- Total assets
- $208.2B
- Current assets
- $42.9B
- Total liabilities
- $121.4B
- Current liabilities
- $37.0B
- Shareholders’ equity
- $86.8B
Cash flow
- Operating cash flow
- $11.7B
- Investing cash flow
- -$1.4B
- Financing cash flow
- -$10.3B
- Net cash flow
- $90.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $148.4B
- P/E ratio
- 18.8
- EPS (diluted)
- $1.36
- Dividend yield
- 6.71%
- Shares outstanding
- 5.8B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 22, 1951
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $7.8B in FY2025.
- Revenue declined 23% from FY2021 to FY2025.
- Gross margin of 74.3%, net margin 12.5%.
- Trading 10% below its 52-week high.
- Pays a dividend yielding about 6.71% annually.
- Valued at a price-to-earnings (P/E) ratio of 18.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PFIZER INC.
Write a review
News about PFIZER INC
News & sentiment via Polygon.io
